美国 · 股市与财经 · The Motley Fool
Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield
As it stands, roughly one-third of Pfizer's revenue is subject to patent expirations over the next couple of years. It's nothing to dismiss. Largely lost in the matter, however,…
在 The Motley Fool 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.fool.com)
